Faruqi and Faruqui, LLP Logo
Share this page

Tetraphase Pharmaceuticals, Inc. (TTPH)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Tetraphase Pharmaceuticals, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ:TTPH) of the March 28, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased Tetraphase securities between March 5, 2015 and September 8, 2015 (the “Class Period”).  The case, Harrington v. Tetraphase Pharmaceuticals Inc. et al, No. 1:16-cv-10133 (D. Mass. Jan 28, 2016) was filed on January 28, 2016, and has been assigned to Judge Leo T. Sorokin.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting the capacity for clinical approval of Eravacycline, an intravenous (IV) to oral transition therapy for the treatment of complicated urinary tract infections, by both the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency (“EMA”).

Specifically, on September 8, 2015, Tetraphase announced negative results of the pivotal portion of Eravacycline during the IGNITE2 phase 3 clinical trial. The Company disclosed that Eravacycline had failed to achieve its primary endpoint of statistical non-inferiority compared to Levofloxacin under the guidelines established by both the FDA and EMA.

After this announcement, Tetraphase’s share price fell from $44.78 per share on September 8, 2015 to a closing price of $8.36 on September 10, 2015—a $36.42 or a 81.3% drop.

Take Action

If you invested in Tetraphase securities between March 5, 2015 and September 8, 2015 and would like to discuss your legal rights, please contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Tetraphase’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Tetraphase Pharmaceuticals, Inc. (TTPH)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 02/08/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.